Dianthus Therapeutics, Inc. /DE/
Business
Dianthus Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins for severe autoimmune diseases. Its lead candidate, claseprubart, is a selective C1s complement inhibitor engineered for extended half-life and infrequent subcutaneous dosing, currently in Phase 2/3 trials for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company's second candidate, DNTH212, is a bifunctional BDCA2 and BAFF/APRIL inhibitor licensed from Nanjing Leads Biolabs, in early Phase 1 development. Dianthus holds worldwide development and commercialization rights outside Greater China, with regional licensing agreements for China and related territories.
Summary from 10-K filed 2026-03-09
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 2 | 6 | 3 | — | — | |
| Research and development | 146 | 83 | 33 | 29 | 47 | |
| General and administrative | 34 | 25 | 18 | 7 | 28 | |
| Total operating expenses | 180 | 108 | 51 | 36 | 75 | |
| Loss from operations | −178 | −102 | −48 | −30 | −75 | |
| Interest and investment income | 16 | 17 | — | — | — | |
| Gain on investment in former related party | 508,000 | 148,000 | — | — | — | |
| Loss on currency exchange, net | −57,000 | −64,000 | −85,000 | 136,000 | — | |
| Other expense | −974,000 | −554,000 | −60,000 | −52,000 | — | |
| Total other income | 16 | 17 | 5 | 1 | — | |
| Net loss | −162 | −85 | −44 | −29 | −71 | |
| Net loss per share attributable to common stockholders, basic | −4.2 | −2.55 | −8.45 | −32.57 | −1.29 | |
| Net loss per share attributable to common stockholders, diluted | −4.2 | −2.55 | −8.45 | −32.57 | −1.29 | |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic | 39 | 33 | 5 | 874,234 | 55 | |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, diluted | 39 | 33 | 5 | 874,234 | 55 | |
| Unrealized gain on marketable securities | 383,000 | 59,000 | 208,000 | −161,000 | −7,000 | |
| Total other comprehensive income | 383,000 | 59,000 | 208,000 | −161,000 | −7,000 | |
| Total comprehensive loss | −162 | −85 | −43 | −29 | −71 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 51 | 23 | 132 | 15 | 132 | |
| Short-term investments | 353 | 252 | 41 | 60 | — | |
| Receivable from former related party | 0 | 807,000 | — | — | — | |
| Accounts receivable, net | 52,000 | 0 | 294,000 | 5 | — | |
| Prepaid expenses and other current assets | 5 | 5 | 3 | 905,000 | 4 | |
| Total current assets | 409 | 281 | 177 | 82 | 181 | |
| Long-term investments | 110 | 82 | 0 | — | — | |
| Property and equipment, net | 296,000 | 194,000 | 185,000 | 142,000 | 7 | |
| Right-of-use operating lease assets | 1 | 2 | 615,000 | 814,000 | 0 | |
| Other assets and restricted cash | 10 | 10 | 1 | 121,000 | — | |
| Total assets | 531 | 374 | 179 | 83 | 190 | |
| Accounts payable | 10 | 5 | 3 | 1 | 3 | |
| Accrued expenses | 19 | 13 | 7 | 7 | — | |
| Current portion of deferred revenue | 1 | 479,000 | 0 | 100,000 | — | |
| Current portion of operating lease liabilities | 367,000 | 320,000 | 417,000 | 350,000 | 0 | |
| Total current liabilities | 31 | 18 | 10 | 8 | 11 | |
| Deferred revenue | 6 | 2 | 0 | 791,000 | — | |
| Long-term operating lease liabilities | 1 | 1 | 168,000 | 438,000 | 0 | |
| Total liabilities | 38 | 22 | 11 | 9 | 17 | |
| Commitments and contingencies (Note 16) | — | — | — | — | — | |
| Preferred stock; $0.001 par value per share; authorized shares - 10,000,000 at December 31, 2025 and 2024; issued and outstanding - none at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock; $0.001 par value per share; authorized shares - 150,000,000 at December 31, 2025 and 2024; issued and outstanding shares - 43,223,090 and 31,115,341 at December 31, 2025 and 2024, respectively | 43,000 | 31,000 | 15,000 | 0 | 59,000 | |
| Additional paid-in capital | 830 | 527 | 258 | 2 | 498 | |
| Accumulated deficit | −337 | −174 | −89 | −46 | −326 | |
| Accumulated other comprehensive income | 489,000 | 106,000 | 47,000 | −161,000 | −30,000 | |
| Total stockholders' equity | 493 | 352 | 169 | −44 | −17 | |
| Total liabilities and stockholders 'equity | 531 | 374 | 179 | 83 | 190 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −162 | −85 | −44 | −28 | −71 | |
| Depreciation expense | 100,000 | 100,000 | 67,000 | 30,000 | — | |
| Stock-based compensation expense | 23 | 13 | 3 | 2 | 10 | |
| Accretion of discount on investment securities | −6 | −6 | −1 | −606,000 | — | |
| Amortization of right-of-use operating lease assets | 317,000 | 316,000 | 288,000 | 117,000 | — | |
| Gain on investment in former related party | −507,000 | −148,000 | — | — | — | |
| Receivable from former related party | 807,000 | −513,000 | — | — | — | |
| Unbilled receivable from former related party | 0 | 184,000 | — | — | — | |
| Accounts receivable, net | −52,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | −235,000 | −2 | 123,000 | −631,000 | −1 | |
| Other assets | 358,000 | −8 | −1 | −31,000 | — | |
| Accounts payable, accrued expenses and operating lease liabilities | 11 | 8 | 661,000 | — | — | |
| Deferred revenue | 5 | 2 | 0 | 891,000 | — | |
| Deferred revenue - former related party | 0 | −836,000 | — | — | — | |
| Net cash used in operating activities | −129 | −78 | −37 | −29 | −60 | |
| Capital expenditures | −213,000 | −105,000 | −110,000 | −139,000 | — | |
| Purchases of investment securities | −435 | −414 | −57 | — | — | |
| Proceeds from sales and maturities of investment securities | 312 | 127 | 78 | — | — | |
| Net cash used in investing activities | −123 | −287 | 20 | −60 | 43 | |
| Proceeds from public offering | 272 | 0 | — | — | — | |
| Payment of issuance costs in connection with public offering | −364,000 | 0 | — | — | — | |
| Proceeds from exercise of stock options | 8 | 1 | 5,000 | 0 | 3 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 317,000 | 0 | 0 | 3 | 0 | |
| Proceeds from exercise of pre-funded warrants | 1,000 | 0 | — | — | — | |
| Proceeds from private placement | 0 | 230 | 0 | — | — | |
| Payment of issuance costs in connection with the private placement | 0 | −15 | 0 | 0 | −303,000 | |
| Proceeds from issuance of common stock pursuant to ATM offering, net of issuance costs | 0 | 39 | — | — | — | |
| Net cash provided by financing activities | 280 | 256 | 134 | 97 | 90 | |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 28 | −109 | 117 | 8 | 73 | |
| Cash paid for interest | 0 | 0 | 0 | 0 | — | |
| Cash paid for taxes | 0 | 0 | 0 | 0 | — | |
| Issuance costs in connection with public offering included in accrued expenses | 40,000 | 0 | — | — | — | |
| Additions to right-of-use lease assets from new operating lease liabilities | 101,000 | 1 | 89,000 | 931,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Dianthus Therapeutics, Inc. /DE/'s CIK number?
Dianthus Therapeutics, Inc. /DE/'s SEC CIK number is 0001690585 (1690585). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Dianthus Therapeutics, Inc. /DE/'s SEC filings?
All of Dianthus Therapeutics, Inc. /DE/'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Dianthus Therapeutics, Inc. /DE/ last report earnings?
Dianthus Therapeutics, Inc. /DE/ (DNTH) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001690585-26-000021). This is Dianthus Therapeutics, Inc. /DE/'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Dianthus Therapeutics, Inc. /DE/'s most recent earnings 8-K?
Dianthus Therapeutics, Inc. /DE/'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001690585-26-000021. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Dianthus Therapeutics, Inc. /DE/'s latest earnings 8-K →
Look up any company's CIK number →